A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia

Schizophrenia Research

Volumn 153, Issue 1-3, 2014, Pages 160-168

  Weiden, Peter J ^a   Citrome, Leslie ^b   Alva, Gus ^c   Brams, Matthew ^d   Glick, Ira D ^e   Jackson, Richard ^f   Mattingly, Greg ^g   Kianifard, Farid ^h   Meng, Xiangyi ^h   Pestreich, Linda ^h,i   Hochfeld, Marla ^h,j   Winseck, Adam ^h  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c ATP Clinical Research   (United States)

^d Memorial Park Psychiatry   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^j CELGENE CORPORATION   (United States)

more..

Author keywords

Clinical improvement; Iloperidone; Safety; Schizophrenia; Switch strategy; Tolerability

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; GLUCOSE; ILOPERIDONE; OLANZAPINE; PROLACTIN; RISPERIDONE; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ANXIETY DISORDER; APPENDICITIS; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS PERFORATION; FAINTNESS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NOSE OBSTRUCTION; OPEN STUDY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SCHIZOPHRENIA; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; ADOLESCENT; ANALYSIS OF VARIANCE; AORTA CHEMORECEPTOR; COHORT ANALYSIS; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PROCEDURES; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; YOUNG ADULT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; AORTIC BODIES; BENZODIAZEPINES; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PIPERAZINES; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895787295     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.11.042     Document Type: Article

References (21)

1. Agid O., Arenovich T., Sajeev G., Zipursky R.B., Kapur S., Foussias G., Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotics trials with a retrospective data analysis. J. Clin. Psychiatry. 2011, 72:1439-1444.
2. Atkinson M.J., Sinha A., Hass S.L., Colman S.S., Kumar R.N., Brod M., Rowland C.R. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health. Qual. Life. Outcomes. 2004, 2:12.
3. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., Ingenito G.G. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl.). 2003, 166:391-399.
4. Cha D.S., McIntyre R.S. Treatment-emergent adverse events associated with atypical antipsychotics. Expert. Opin. Pharmacother. 2012, 13:1587-1598.
5. Cutler A.J., Kalali A.H., Weiden P.J., Hamilton J., Wolfgang C.D. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J. Clin. Psychopharmacol. 2008, 28(2 Suppl. 1):S20-S28.
6. Essock S.M., Covell N.H., Davis S.M., Stroup T.S., Rosenheck R.A., Lieberman J.A. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry. 2006, 163:2090-2095.
7. Fanapt (iloperidone) Prescribing Information, 2013. East Hanover, NJ, Novartis Pharmaceuticals Corporation.
8. Guy W. CGI clinical global impressions. ECDEU Assessment Manual for Psychopharmacology, Revised 1976, 218-222. National Institute for Mental Health, Rockville, MD.
9. Kane J.M., Lauriello J., Laska E., Di Marino M., Wolfgang C.D. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J. Clin. Psychopharmacol. 2008, 28:S29-S35.
10. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta. Psychiatr. Scand. 2009, (Suppl. 7-14).
11. Leucht S., Engel R.R. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology. 2006, 31:406-412.
12. Levine S.Z., Rabinowitz J., Engel R., Etschel E., Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr. Res. 2008, 98:318-322.
13. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
14. Peluso M.J., Lewis S.W., Barnes T.R., Jones P.B. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br. J. Psychiatry. 2012, 200:387-392.
15. Potkin S.G., Litman R.E., Torres R., Wolfgang C.D. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J. Clin. Psychopharmacol. 2008, 28(Suppl. 1):S4-S11.
16. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life. Sci. 2000, 68:29-39.
17. Targum S.D., Pestreich L., Reksoprodjo P., Pereira H., Guindon C., Hochfeld M. A global measure to assess switching antipsychotic medications in the treatment of schizophrenia. Hum. Psychopharmacol. 2012, 27:455-463.
18. Weiden P.J. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin. Schizophr. Relat. Psychoses. 2012, 6:34-44.
19. Weiden P.J., Cutler A.J., Polymeropoulos M.H., Wolfgang C.D. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J. Clin. Psychopharmacol. 2008, 28(2 Suppl. 1):S12-S19.
20. Weiden P.J., Daniel D.G., Simpson G., Romano S.J. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J. Clin. Psychopharmacol. 2003, 23:595-600.
21. Weiden P.J., Simpson G.M., Potkin S.G., O'Sullivan R.L. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J. Clin. Psychiatry. 2003, 64:580-588.